BRIEF-Biostime International Holdings proposes to conduct international senior notes offering
* Proposes to conduct international offering of US$150 million aggregate principal amount of its 7.25% senior notes due 2021
Dec 22 Neuroderm Ltd
* Neuroderm announces completion of patient enrollment and treatment in a Phase II trial of ND0612H for advanced Parkinson's disease
* Topline results from this trial are expected in Q1 of 2017. Source text for Eikon: Further company coverage:
SYDNEY, Jan 23 The Australian government on Monday said it would establish a new Critical Infrastructure Centre to protect key national infrastructure from sabotage, espionage and coercion.
* LME faces struggle to compete with New York, Shanghai futures